| scholarly article | Q13442814 |
| P50 | author | David Andes | Q75205210 |
| P2093 | author name string | William A Craig | |
| Alexander J Lepak | |||
| Karen Marchillo | |||
| Solen Pichereau | |||
| P2860 | cites work | Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic | Q24614464 |
| Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States | Q25257335 | ||
| Invasive methicillin-resistant Staphylococcus aureus infections in the United States | Q29616087 | ||
| Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surve | Q33181940 | ||
| Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections | Q33347869 | ||
| Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin | Q44721295 | ||
| Effect of linezolid compared with glycopeptides in methicillin-resistant Staphylococcus aureus severe pneumonia in piglets. | Q46164703 | ||
| Linezolid pharmacodynamics with Staphylococcus aureus in an in vitro dynamic model | Q46190931 | ||
| Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia | Q46589068 | ||
| Antimicrobial Resistance: Pharmacokinetics‐Pharmacodynamics of Antimicrobial Therapy: It’s Not Just for Mice Anymore | Q58033538 | ||
| Linezolid in Methicillin-Resistant Staphylococcus aureus Nosocomial Pneumonia: A Randomized, Controlled Study | Q64028001 | ||
| Epidemiology of methicillin-resistant Staphylococcus aureus | Q81230327 | ||
| Predictors of clinical virulence in community-onset methicillin-resistant Staphylococcus aureus infections: the importance of USA300 and pneumonia | Q84863175 | ||
| In vitro activity of tedizolid (TR-700) against linezolid-resistant staphylococci | Q85004702 | ||
| In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: application to breakpoint determinations. | Q33697003 | ||
| Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999-2005 | Q33877838 | ||
| Intrapulmonary pharmacokinetics of linezolid | Q34106719 | ||
| Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models | Q34108149 | ||
| In vivo pharmacodynamics of a new oxazolidinone (linezolid) | Q34142754 | ||
| Pharmacodynamics of the new des-f(6)-quinolone garenoxacin in a murine thigh infection model | Q34230600 | ||
| Pharmacodynamics of a new streptogramin, XRP 2868, in murine thigh and lung infection models | Q34301626 | ||
| Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. | Q34307105 | ||
| In Vivo Pharmacodynamics of New Lipopeptide MX-2401 | Q34309486 | ||
| Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints | Q34431984 | ||
| Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections. | Q34529205 | ||
| Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing | Q34647337 | ||
| In vitro activity of TR-700, the active ingredient of the antibacterial prodrug TR-701, a novel oxazolidinone antibacterial agent | Q34986954 | ||
| Morbidity and cost burden of methicillin-resistant Staphylococcus aureus in early onset ventilator-associated pneumonia | Q34999661 | ||
| In vivo pharmacodynamic activity of daptomycin | Q35005549 | ||
| In vivo pharmacodynamics of torezolid phosphate (TR-701), a new oxazolidinone antibiotic, against methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains in a mouse thigh infection model | Q35065908 | ||
| In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis | Q35091285 | ||
| Impact of granulocytes on the antimicrobial effect of tedizolid in a mouse thigh infection model | Q35364245 | ||
| Epidemiology of methicillin-resistant staphylococci in Europe. | Q35612051 | ||
| In vivo pharmacodynamic activity of the glycopeptide dalbavancin | Q35759076 | ||
| Comparative in vivo efficacies of epithelial lining fluid exposures of tedizolid, linezolid, and vancomycin for methicillin-resistant Staphylococcus aureus in a mouse pneumonia model | Q35941253 | ||
| Pulmonary disposition of tedizolid following administration of once-daily oral 200-milligram tedizolid phosphate in healthy adult volunteers | Q35941279 | ||
| Comparative efficacies of human simulated exposures of tedizolid and linezolid against Staphylococcus aureus in the murine thigh infection model | Q36171683 | ||
| Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Te | Q36855581 | ||
| Community-acquired necrotizing pneumonia due to methicillin-sensitive Staphylococcus aureus secreting Panton-Valentine leukocidin: a review of case reports | Q37970828 | ||
| Pharmacodynamic activity and efficacy of linezolid in a rat model of pneumococcal pneumonia | Q39651829 | ||
| Comparative in vitro antimicrobial activities of torezolid (TR-700), the active moiety of a new oxazolidinone, torezolid phosphate (TR-701), determination of tentative disk diffusion interpretive criteria, and quality control ranges | Q40334689 | ||
| Comparative activities of TR-700 (torezolid) against staphylococcal blood isolates collected in Spain. | Q40336550 | ||
| In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains. | Q41389487 | ||
| Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. | Q41696128 | ||
| Mutations in ribosomal protein L3 are associated with oxazolidinone resistance in staphylococci of clinical origin. | Q41897387 | ||
| Novel ribosomal mutations in Staphylococcus aureus strains identified through selection with the oxazolidinones linezolid and torezolid (TR-700). | Q42024058 | ||
| Comparative In Vitro Activities of Torezolid (DA-7157) against Clinical Isolates of Aerobic and Anaerobic Bacteria in South Korea | Q42111215 | ||
| Usefulness of linezolid in the treatment of hospital-acquired pneumonia caused by MRSA: a prospective observational study | Q43703140 | ||
| Pharmacokinetics, toxicokinetics, distribution, metabolism and excretion of linezolid in mouse, rat and dog. | Q44206806 | ||
| Intrapulmonary penetration of linezolid | Q44440587 | ||
| Efficacy of linezolid compared to vancomycin in an experimental model of pneumonia induced by methicillin-resistant Staphylococcus aureus in ventilated pigs | Q44486335 | ||
| Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia | Q44647040 | ||
| Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme | Q44692777 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Staphylococcus aureus | Q188121 |
| pneumonia | Q12192 | ||
| linezolid | Q411377 | ||
| pharmacodynamics | Q725307 | ||
| P304 | page(s) | 5916-5922 | |
| P577 | publication date | 2012-09-10 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Comparative pharmacodynamics of the new oxazolidinone tedizolid phosphate and linezolid in a neutropenic murine Staphylococcus aureus pneumonia model | |
| P478 | volume | 56 |
| Q38117578 | Antimicrobial treatment of febrile neutropenia: pharmacokinetic-pharmacodynamic considerations |
| Q37538738 | Comparative In Vivo Efficacies of Tedizolid in Neutropenic versus Immunocompetent Murine Streptococcus pneumoniae Lung Infection Models |
| Q40675142 | Comparative efficacies of tedizolid phosphate, vancomycin, and daptomycin in a rabbit model of methicillin-resistant Staphylococcus aureus endocarditis |
| Q38255366 | Early experience with tedizolid: clinical efficacy, pharmacodynamics, and resistance |
| Q55250490 | Effect of food on the pharmacokinetic characteristics of a single oral dose of LCB01-0371, a novel oxazolidinone antibiotic. |
| Q40257051 | In Vivo Pharmacokinetics and Pharmacodynamics of ZTI-01 (Fosfomycin for Injection) in the Neutropenic Murine Thigh Infection Model against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa. |
| Q52611991 | In vitro and in vivo activities of DS-2969b, a novel GyrB inhibitor, and its water-soluble prodrug, DS11960558, against methicillin-resistant Staphylococcus aureus. |
| Q36969769 | In vitro, in vivo, and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactions |
| Q64072703 | In vivo pharmacodynamics of lefamulin, the first systemic pleuromutilin for human use, in a neutropenic murine thigh infection model |
| Q35105932 | In vivo pharmacokinetics and pharmacodynamics of the lantibiotic NAI-107 in a neutropenic murine thigh infection model |
| Q37339287 | Linezolid for Infants and Toddlers With Disseminated Tuberculosis: First Steps |
| Q38179460 | New pharmacological treatments for methicillin-resistant Staphylococcus aureus infections |
| Q58788178 | Target site pharmacokinetics of linezolid after single and multiple doses in diabetic patients with soft tissue infection |
| Q33420646 | Tedizolid Phosphate: a Next-Generation Oxazolidinone |
| Q24561509 | Tedizolid phosphate (sivextro): a second-generation oxazolidinone to treat acute bacterial skin and skin structure infections |
| Q38536296 | Tedizolid: The First Once-Daily Oxazolidinone Class Antibiotic |
| Q34660917 | Tedizolid: a new oxazolidinone antimicrobial. |
| Q38352171 | Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens. |
| Q99633705 | Telacebec (Q203)-containing intermittent oral regimens sterilized mice infected with Mycobacterium ulcerans after only 16 doses |
| Q38171760 | Use of pharmacokinetic/pharmacodynamic systems analyses to inform dose selection of tedizolid phosphate |
Search more.